NEW YORK (GenomeWeb) – Editas Medicine is planning a public offering of 4 million shares of common stock, according to a document filed with the US Securities and Exchange Commission.

The Cambridge, Massachusetts-based firm said in a statement that it plans to use the proceeds to fund pre-clinical studies and clinical trials for CRISPR-based human therapies, specifically eye diseases, including Leber congenital amaurosis (LCA) 10.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.